Treprostinil Sodium: Revolutionizing Pulmonary Arterial Hypertension Treatment
1.What is Treprostinil Sodium?
Treprostinil Sodium is a stable, long-acting prostacyclin analog designed to mimic the natural vasodilatory and antiplatelet effects of prostacyclin. It works by dilating pulmonary arteries, reducing vascular resistance, and improving blood flow in PAH patients. Approved by regulatory bodies like the FDA and EMA, it is available in multiple formulations: intravenous (IV), subcutaneous (SC), oral, and inhaled, providing flexibility tailored to patient needs.
2.Key Benefits and Clinical Applications
Treprostinil Sodium is primarily prescribed for PAH (WHO Group 1) to alleviate symptoms such as shortness of breath, fatigue, and chest pain, while enhancing exercise capacity and delaying disease progression. Clinical trials have demonstrated its efficacy in improving hemodynamics and quality of life, both as a monotherapy and in combination with other PAH-specific medications like endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors.
Core Indications:
- Idiopathic/hereditary PAH: PAH of unknown etiology or associated with a genetic mutation, such as the BMPR2 gene.
- Secondary PAH:
- Connective tissue diseases associated with PAH: such as systemic sclerosis, lupus erythematosus, etc.
- HIV infection-associated PAH: Vascular lesions caused by HIV infection.
- Congenital heart disease-associated PAH : Remodeling of pulmonary blood vessels due to partial congenital heart defects.
- Intravenous/subcutaneous injection : For severe patients, continuous infusion is required.
- Oral tablets : For patients with stable conditions to improve the convenience of medication.
- Inhaled dosage form : Targets the lungs, reduces systemic side effects (e.g., headache, diarrhea)
- Chronic thromboembolic pulmonary Hypertension (CTEPH, WHO Category 4):
Some studies have shown that Treprostinil Sodium may improve hemodynamics in inoperable CTEPH patients, but it has not yet become standard therapy.
- Pulmonary hypertension associated with left heart Disease (WHO Category 2) :
- There is limited evidence and more clinical studies are needed to verify its effectiveness.
- Reynolds Phenomenon :
- As a vasodilator, may relieve the vasospasm symptoms of Raynaud's syndrome.
- Heart failure (HF) with pulmonary hypertension:
- To explore its effects on right heart function and pulmonary vascular resistance in patients with heart failure.
- Acute Respiratory Distress Syndrome (ARDS)
- To investigate its potential to improve oxygenation and pulmonary vascular function in COVID-19 associated lung injury.
We have a strong professional R&D team, excellent talents and well-equipped laboratories for quality control.
All products are in accordance with international standards, with more than five years of experience in technical inspection personnel, with advanced testing equipment, with their own independent, fully equipped testing laboratory, and strive to provide customers with high quality products and services.
